Hsbc Holdings PLC Has $412,000 Stake in Amicus Therapeutics, Inc. $FOLD

Hsbc Holdings PLC boosted its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 20.4% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 50,456 shares of the biopharmaceutical company’s stock after buying an additional 8,536 shares during the period. Hsbc Holdings PLC’s holdings in Amicus Therapeutics were worth $412,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Virtus Fund Advisers LLC acquired a new position in shares of Amicus Therapeutics during the fourth quarter valued at about $29,000. PNC Financial Services Group Inc. raised its holdings in shares of Amicus Therapeutics by 211.4% during the first quarter. PNC Financial Services Group Inc. now owns 5,151 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 3,497 shares during the period. GF Fund Management CO. LTD. acquired a new position in shares of Amicus Therapeutics during the fourth quarter valued at about $59,000. GAMMA Investing LLC raised its holdings in shares of Amicus Therapeutics by 1,610.8% during the first quarter. GAMMA Investing LLC now owns 7,442 shares of the biopharmaceutical company’s stock valued at $61,000 after purchasing an additional 7,007 shares during the period. Finally, Bryce Point Capital LLC acquired a new position in shares of Amicus Therapeutics during the first quarter valued at about $100,000.

Amicus Therapeutics Trading Up 3.8%

FOLD opened at $7.88 on Wednesday. The company has a debt-to-equity ratio of 1.92, a current ratio of 3.21 and a quick ratio of 2.29. Amicus Therapeutics, Inc. has a fifty-two week low of $5.51 and a fifty-two week high of $12.65. The firm has a market capitalization of $2.43 billion, a PE ratio of -65.66 and a beta of 0.55. The company’s 50-day moving average is $6.61 and its 200 day moving average is $7.08.

Analyst Ratings Changes

Several equities analysts have recently weighed in on FOLD shares. Wall Street Zen lowered shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday. Morgan Stanley upgraded shares of Amicus Therapeutics from an “equal weight” rating to an “overweight” rating in a report on Thursday, July 17th. Eight investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $16.22.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.